TRANSCEND MEDICAL

Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70 million worldwide by the year 2015. In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial.